Published in Physician Law Weekly, July 1st, 2009
"With this marketing authorization, Renvela is the first phosphate binder for patients not on dialysis approved through the centralized procedure in Europe," said Dan Regan, Senior Vice President and General Manager of Genzyme's renal business. "This is an important step toward improved patient care, and we are pleased...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly